Regulus Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Regulus Therapeutics Inc.
Sanofi has abandoned its study of lademirsen in Alport disease, but has not given up on the drug just yet as another indication remains in play.
Companies such as Novartis, Roche or Takeda are heavily invested in the advanced therapeutics field, usually spreading their bets across multiple modalities. The remaining challenges offer opportunities for the next wave of innovation to transform the field once again and make a dent in the larger market of common diseases and solid tumors.
Initial public offering momentum decelerated as stock prices declined last year, but even with lower valuations making M&A more attractive, the IPO market this year is expected to be active.
Last year proved to be another record period for securities class actions, with a 13% increase in cases filed compared with 2018, and a 24% increase in claims brought against life sciences companies compared with 2018, according to a report by Cornerstone Research: Securities Class Action Filings: 2019 Year In Review.
- Antisense, Oligonucleotides
- Large Molecule
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.